The NHS continued: "Apixaban can sometimes cause serious side effects, but most of them are rare. A more common serious side ...
Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher ...
Since the introduction of durable left ventricular assist devices for advanced heart failure, management of antithrombotic ...
At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...
The NHS listed a number of "serious" side effects of this drug ...
Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...
Very elderly people with nonvalvular atrial fibrillation (Afib) got the same stroke prevention benefits from edoxaban (Savaysa) and apixaban (Eliquis), though one drug was associated with more major ...
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of non-valvular atrial fibrillation and the value ...
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results